SyneuRx International (Taiwan) Corp.

TPEX:6575 Stock Report

Market Cap: NT$2.1b

SyneuRx International (Taiwan) Balance Sheet Health

Financial Health criteria checks 4/6

SyneuRx International (Taiwan) has a total shareholder equity of NT$276.6M and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$323.4M and NT$46.8M respectively.

Key information

0%

Debt to equity ratio

NT$0

Debt

Interest coverage ration/a
CashNT$180.84m
EquityNT$276.58m
Total liabilitiesNT$46.79m
Total assetsNT$323.37m

Recent financial health updates

Recent updates

SyneuRx International (Taiwan) (GTSM:6575) Is In A Good Position To Deliver On Growth Plans

Mar 10
SyneuRx International (Taiwan) (GTSM:6575) Is In A Good Position To Deliver On Growth Plans

We Think SyneuRx International (Taiwan) (GTSM:6575) Can Afford To Drive Business Growth

Nov 25
We Think SyneuRx International (Taiwan) (GTSM:6575) Can Afford To Drive Business Growth

Financial Position Analysis

Short Term Liabilities: 6575's short term assets (NT$278.6M) exceed its short term liabilities (NT$22.1M).

Long Term Liabilities: 6575's short term assets (NT$278.6M) exceed its long term liabilities (NT$24.6M).


Debt to Equity History and Analysis

Debt Level: 6575 is debt free.

Reducing Debt: 6575 has no debt compared to 5 years ago when its debt to equity ratio was 0.02%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6575 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 6575 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.3% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/01/29 13:49
End of Day Share Price 2023/01/06 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SyneuRx International (Taiwan) Corp. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution